Wen Yumei, Wang Xuanyi, Wang Bin, Yuan Zhenhong
Key Laboratory Medical Molecular Virology of Ministry of Education/Ministry of Health, Shanghai Medical College, Fudan University, Shanghai, 200032, China,
Front Med. 2014 Mar;8(1):17-23. doi: 10.1007/s11684-014-0313-7. Epub 2014 Jan 24.
Chronic hepatitis B is a major health burden worldwide. In addition to the recent progress in antiviral treatment, therapeutic vaccination is a promising new strategy for the control of chronic hepatitis B. On the basis of the major specific and non-specific immune dysregulations and defects in chronic hepatitis B patients, this paper presents the peptide and protein-based, DNA-based, cell-based, and antigen-antibody-based therapeutic vaccines, which have undergone clinical trials. The advantages, disadvantages, and future perspectives for these therapeutic vaccines are discussed.
慢性乙型肝炎是全球主要的健康负担。除了抗病毒治疗方面的最新进展外,治疗性疫苗接种是控制慢性乙型肝炎的一种有前景的新策略。基于慢性乙型肝炎患者主要的特异性和非特异性免疫失调及缺陷,本文介绍了已进行临床试验的基于肽和蛋白质、基于DNA、基于细胞以及基于抗原-抗体的治疗性疫苗。并讨论了这些治疗性疫苗的优缺点及未来前景。